CAR-T

#Biologics #CAR-T #Cell and gene therapy #Cell therapy #PCR #Whitepaper

Whitepaper on digital PCR for lentiviral vector characterisation

A new Whitepaper is available from Thermo Fisher Scientific, entitled ‘Lentiviral vector characterization for cell and gene therapy manufacturing using the QuantStudio Absolute Q Digital PCR System’. Recombinant lentiviral vectors are used for ex vivo transgene delivery in several gene-modified cell therapies, such as chimeric antigen receptor (CAR) T cell therapy. Read More

#News

#Biologics #CAR-T #Cell and gene therapy #Cell therapy #PCR

Explore the power of digital PCR for lentiviral vector characterisation

Recombinant lentiviral vectors are used for ex vivo transgene delivery in several gene-modified cell therapies, such as chimeric antigen receptor (CAR) T cell therapy. Reliable analytical methods such as digital PCR to characterise lentiviral vectors and the cells transduced with them are critical to helping ensure the safety and efficacy of… Read More

#Resources

#Cancer research #CAR-T #Cell and gene therapy #Collaboration #Oncology #Solid tumours

New DDW Highlights podcast now live

The latest episode of the DDW Highlights podcast is now available to listen to below. DDW’s Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry updates.  The news headlines this week reflect the level of interest in cell & gene… Read More

#News

#Cancer research #CAR-T #Cell and gene therapy #Collaboration #Oncology #Solid tumours

This week in drug discovery (7-11 August)  

News round-up for by DDW Digital Content Editor Diana Spencer. The news headlines this week reflect the level of interest in cell & gene therapies (CGT) in the sector, particularly CAR-T, but also the importance of research collaborations to bring these therapies to patients. Traditionally successful… Read More

#News

CAR-T therapy
#Cancer research #CAR-T #Collaboration #GenScript Biotech #Solid tumours #T-MAXIMUM Biotech

Collaborators agree deal to develop CAR-T therapy for solid tumours

GenScript Biotech and T-MAXIMUM Biotech have formed a strategic collaboration to develop T-MAXIMUM's CAR-T cell therapy using GenScript's CRISPR nucleic acid reagents. GenScript will provide various CRISPR reagents to support the development of the universal CAR-T products from discovery to commercialisation. T-MAXIMUM Biotech hopes to progress multiple products to the… Read More

#Business & Investment #News

CAR-T therapy
#Aleta Biotherapeutics #Biologics #Cancer research #Cancer Research UK #CAR-T #MHRA #Oncology

Biologic CAR-T cell engager approved for UK clinical trial

The UK Medicines and Healthcare products Regulatory Agency (MHRA) has granted Aleta Biotherapeutics a clinical trial authorisation (CTA) to evaluate biologic ALETA-001 in a Phase I/II clinical trial in patients with B-cell malignancies who are relapsed/refractory to CD19 CAR-T cell therapy. The company’s collaboration partner, Cancer Research UK’s Centre for… Read More

#Cancer Research #News #Regulatory

CAR-T cells attack cancer cells
#Astellas Pharma #Cancer research #CAR-T #Cell therapy #Investment #Poseida Therapeutics #Solid tumours

Astellas invests in CAR-T cell therapy for solid tumours

Astellas Pharma will invest $50 million into Poseida Therapeutics to secure the rights to the company’s cancer CAR-T cell therapy for solid tumours, which is currently in Phase I trials. The total $50 million will include $25 million to acquire 8,333,333 shares of common stock of Poseida and a one-time… Read More

#Business & Investment #News

Advanced therapies
#Advanced Therapies #CAR-T #Cell and gene therapy #Drug development

Commercialising advanced therapies: Industry perspectives 

Dr Christian K Schneider, Head of Biopharma Excellence at PharmaLex, presents the findings of an industry panel debate on barriers to commercialisation of novel treatments, and the most effective strategies to bring them to market.  With so many exciting novel treatments emerging from the labs, biotechs and pharma companies need… Read More

#Exclusive Content #Opinion

Genetic research
#CAR-T #Drug development #Drug discovery #Synthetic biology

Synthetic biology: Innovating in drug discovery

Listen to this article on the DDW Podcast: Synthetic biology is increasingly important to drug discovery and development. Reece Armstrong examines recent activity within the sector and highlights some of the key advancements and innovation. Partnerships Earlier this year cell-engineering company MaxCyte signed a strategic platform license (SPL) with biotechnology company… Read More

#Exclusive Content

CRISPR gene editing
#Cancer research #CAR-T #CRISPR #CRISPR-Cas9 #Gene editing #Oncology

CRISPR breakthroughs: New solutions for common diseases

Listen to this article on the DDW Podcast: Rolf Turk, Senior Manager, Genomics Medicine at Integrated DNA Technologies, examines how CRISPR is being used to enhance cancer therapies. Since its discovery in 2012, CRISPR (Clustered Regularly Interspaced Short Palindromic Repeats) technology has revolutionised the biomedicine and cell and gene therapy fields,… Read More

#Cancer Research #Exclusive Content

Cancer cell
#AACR 2023 #Cancer research #CAR-T #DDW Events podcast #Meet the Researcher #T cell receptor (TCR) #Triumvira Immunologics

DDW Events: AACR 2023 Episode 3 with Vito Palombella, Surface Oncology

At the American Association of Cancer Research’s Annual Meeting in Orlando, Florida, DDW’s Megan Thomas met with industry experts to learn more about their research and careers in the field of cancer research. In this latest episode, Thomas speaks with Vito Palombella, Chief Scientific Officer at Surface Oncology. You… Read More

#Podcasts

#AACR 2023 #Cancer research #CAR-T #DDW Events podcast #Meet the Researcher #T cell receptor (TCR) #Triumvira Immunologics

Meet the researcher: Andreas Bader, Triumvira Immunologics

At the American Association of Cancer Research’s Annual Meeting in Orlando, Florida, DDW's Megan Thomas met with industry experts to learn more about their research and careers in the field of cancer research. Thomas speaks with Andreas Bader, Chief Scientific Officer at Triumvira Immunologics. MT: Where do you work, and… Read More

#Cancer Research #Exclusive Content #Opinion

Cancer cells
#AACR 2023 #Cancer research #CAR-T #DDW Events podcast #Meet the Researcher #T cell receptor (TCR) #Triumvira Immunologics

DDW Events: AACR 2023 Episode 2 with Andreas Bader, Triumvira Immunologics

At the American Association of Cancer Research’s Annual Meeting in Orlando, Florida, DDW’s Megan Thomas met with industry experts to learn more about their research and careers in the field of cancer research. In this latest episode, Thomas speaks with Andreas Bader, Chief Scientific Officer at Triumvira Immunologics. You… Read More

#Podcasts

CAR-T therapy
#CAR-T #European Commission #European Medicines Agency #Janssen #Myeloma #Oncology #Phase III trial

Janssen seeks EU approval of new indication for CAR-T therapy

The Janssen Pharmaceutical Companies of Johnson & Johnson have submitted a Type II variation application to the European Medicines Agency (EMA) seeking approval of Carvykti (ciltacabtagene autoleucel; cilta-cel) for relapsed and lenalidomide-refractory multiple myeloma. The application is supported by data from the Phase III CARTITUDE-4 study, which evaluated the safety… Read More

#News #Regulatory

#Advanced Therapies #CAR-T #Cell and gene therapy #Cell therapy #Gene therapy

No sign of stopping: The rise of cell and gene therapy

Listen to this article on the DDW Podcast: Ryan Leahy, a science communication expert in cell and gene therapy, at Phacilitate, says there is a lot to celebrate but also much to assess, question and challenge in this sector. While the global economic landscape faces a major crisis and biotech is… Read More

#Exclusive Content #Opinion